Search

Vascular injury is a well-established, disease-modifying factor in acute respiratory distress syndrome (ARDS) pathogenesis. Recently, coronavirus disease 2019 (COVID-19)–induced injury to the vascular compartment has been linked to complement activation, microvascular thrombosis, and dysregulated immune responses. This study sought to assess whether aberrant vascular activation in this prothrombotic context was associated with the induction of necroptotic vascular cell death. To achieve this, proteomic analysis was performed on blood samples from COVID-19 subjects at distinct time points during ARDS pathogenesis (hospitalized at risk, N= 59; ARDS, N= 31; and recovery, N= 12). Assessment of circulating vascular markers in the at-risk cohort revealed a signature of low vascular protein abundance that tracked with low platelet levels and increased mortality. This signature was replicated in the ARDS cohort and correlated with increased plasma angiopoietin 2 levels. COVID-19 ARDS lung autopsy immunostaining confirmed a link between vascular injury (angiopoietin 2) and platelet-rich microthrombi (CD61) and induction of necrotic cell death [phosphorylated mixed lineage kinase domain-like (pMLKL)]. Among recovery subjects, the vascular signature identified patients with poor functional outcomes. Taken together, this vascular injury signature was associated with low platelet levels and increased mortality and can be used to identify ARDS patients most likely to benefit from vascular targeted therapies.

Biological organisms achieve robust high-level behaviours by combining and coordinating stochastic low-level components1–3. By contrast, most current robotic systems comprise either monolithic mechanisms4,5or modular units with coordinated motions6,7. Such robots require explicit control of individual components to perform specific functions, and the failure of one component typically renders the entire robot inoperable. Here we demonstrate a robotic system whose overall behaviour can be successfully controlled by exploiting statistical mechanics phenomena. We achieve this by incorporating many loosely coupled ‘particles’, which are incapable of independent locomotion and do not possess individual identity or addressable position. In the proposed system, each particle is permitted to perform only uniform volumetric oscillations that are phase-modulated by a global signal. Despite the stochastic motion of the robot and lack of direct control of its individual components, we demonstrate physical robots composed of up to two dozen particles and simulated robots with up to 100,000 particles capable of robust locomotion, object transport and phototaxis (movement towards a light stimulus). Locomotion is maintained even when 20 per cent of the particles malfunction. These findings indicate that stochastic systems may offer an alternative approach to more complex and exacting robots via large-scale robust amorphous robotic systems that exhibit deterministic behaviour.

A limited number of cancer cells within a tumor are thought to have self‐renewing and tumor‐initiating capabilities that produce the remaining cancer cells in a heterogeneous tumor mass. Elucidation of central pathways preferentially used by tumor‐initiating cells/cancer stem cells (CSCs) may allow their exploitation as potential cancer therapy targets. We used single cell cloning to isolate and characterize four isogenic cell clones from a triple‐negative breast cancer cell line; two exhibited mesenchymal‐like and two epithelial‐like characteristics. Within these pairs, one, but not the other, resulted in tumors in immunodeficient NOD/Shi‐scid/IL‐2 Rγ null mice and efficiently formed mammospheres. Quantitative proteomics and phosphoproteomics were used to map signaling pathways associated with the tumor‐initiating ability. Signaling associated with apoptosis was suppressed in tumor‐initiating versus nontumorigenic counterparts with pro‐apoptotic proteins, such as Bcl2‐associated agonist of cell death (BAD), FAS‐associated death domain protein (FADD), and myeloid differentiation primary response protein (MYD88), downregulated in tumor‐initiating epithelial‐like cells. Functional studies confirmed significantly lower apoptosis in tumor‐initiating versus nontumorigenic cells. Moreover, central pathways, including β‐catenin and nuclear factor kappa‐light‐chain‐enhancer of activated B cells (NF‐κB)‐related signaling, exhibited increased activation in the tumor‐initiating cells. To evaluate the CSC model as a tool for drug screening, we assessed the effect of separately blocking NF‐κB and Wnt/β‐catenin signaling and found markedly reduced mammosphere formation, particularly for tumor‐initiating cells. Similar reduction was also observed using patient‐derived primary cancer cells. Furthermore, blocking NF‐κB signaling in mice transplanted with tumor‐initiating cells significantly reduced tumor outgrowth. Our study demonstrates that suppressed apoptosis, activation of pathways associated with cell viability, and CSCs are the major differences between tumor‐initiating and nontumorigenic cells independent of their epithelial‐like/mesenchymal‐like phenotype. These altered pathways may provide targets for future drug development to eliminate CSCs, and the cell model may be a useful tool in such drug screenings. StemCells2017;35:1898–1912 To elucidate signaling pathways preferentially used by breast cancer stem cells (tumor‐initiating cells), but independent of their epithelial‐like/mesenchymal‐like phenotype, we isolated four isogenic cell lines by single cell cloning of a triple‐negative breast cancer cell line and performed quantitative proteomics and phosphoproteomics. Two of the cell line exhibited mesenchymal‐like and two epithelial‐like characteristics. Within these pairs, one, but not the other, resulted in tumors in immunodeficient NOG mice and efficiently formed mammospheres. Quantitative proteomics and phosphoproteomics revealed that the tumor‐initiating cells of both cell types showed down‐regulation of the apoptotic pathway and subsequent functional studies confirmed that tumor‐initiating cells exhibited a lower rate of apoptosis. Further, the tumor‐initiating cells exhibited pathway modulations related to NF‐κB and β‐catenin signaling. The described cell line model is a potentially suitable tool for future drug screening for CSC‐targeting candidates and will provide novel insight to the mechanisms responsible for the tumorigenic phenotype of tumor‐initiating cells in triple‐negative breast cancer.

ABSTRACTThe tumor microenvironment is composed of many immune cell subpopulations and is an important factor in the malignant progression of neoplasms, particularly breast cancer (BC). However, the cytokine networks that coordinate various regulatory events within the BC interstitium remain largely uncharacterized. Moreover, the data obtained regarding the origin of cytokine secretions, the levels of secretion associated with tumor development, and the possible clinical relevance of cytokines remain controversial. Therefore, we profiled 27 cytokines in 78 breast tumor interstitial fluid (TIF) samples, 43 normal interstitial fluid (NIF) samples, and 25 matched serum samples obtained from BC patients with Luminex xMAP multiplex technology. Eleven cytokines exhibited significantly higher levels in the TIF samples compared with the NIF samples: interleukin (IL)-7, IL-10, fibroblast growth factor-2, IL-13, interferon (IFN)γ-inducible protein (IP-10), IL-1 receptor antagonist (IL-1RA), platelet-derived growth factor (PDGF)-β, IL-1β, chemokine ligand 5 (RANTES), vascular endothelial growth factor, and IL-12. An immunohistochemical analysis further demonstrated that IL-1RA, IP-10, IL-10, PDGF-β, RANTES, and VEGF are widely expressed by both cancer cells and tumor-infiltrating lymphocytes (TILs), whereas IP-10 and RANTES were preferentially abundant in triple-negative breast cancers (TNBCs) compared to Luminal A subtype cancers. The latter observation corresponds with the high level of TILs in the TNBC samples. IL-1β, IL-7, IL-10, and PDGFβ also exhibited a correlation between the TIF samples and matched sera. In a survival analysis, high levels of IL-5, a hallmark TH2 cytokine, in the TIF samples were associated with a worse prognosis. These findings have important implications for BC immunotherapy research.